Verastem, Inc. (LON:0LOV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 529.41M +34.4% |
| Revenue (ttm) | 65.97M +3,995.7% |
| Net Income | -152.77M |
| EPS | -1.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,064 |
| Open | 7.67 |
| Previous Close | 7.86 |
| Day's Range | 7.67 - 7.87 |
| 52-Week Range | 3.44 - 10.67 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine ki... [Read more]
Financial Performance
In 2025, Verastem's revenue was $30.91 million, an increase of 209.14% compared to the previous year's $10.00 million. Losses were -$209.47 million, 60.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026.
Verastem initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Verastem (VSTM) with an Outperform rating.
Verastem Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Key programs include a commercial therapy for KRAS-mutated ovarian cancer and the VS-7375 KRAS G12D inhibitor, with phase II and III trials advancing in pancreas, lung, and colorectal cancers. Upcoming data and confirmatory studies aim to expand indications and demonstrate best-in-class efficacy. Major data readouts are expected in the next year.
Verastem Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Significant progress is being made with a highly selective G12D inhibitor across pancreatic, lung, and colorectal cancers, with pivotal data updates and regulatory milestones expected soon. Commercial momentum continues in ovarian cancer, and strategic partnerships are being pursued to support broad clinical development.
Verastem to unveil new clinical data on VS-7375
Verastem (VSTM) Oncology announced it will host an investor event to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the…
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will h...
Verastem Oncology to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
Verastem price target lowered to $13 from $14 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Verastem (VSTM) to $13 from $14 and keeps an Outperform rating on the shares. The firm updated the company’s model…
Verastem price target lowered to $13 from $14 at Mizuho
Mizuho lowered the firm’s price target on Verastem (VSTM) to $13 from $14 and keeps an Outperform rating on the shares following last week’s Q2 report. The firm leaves Q2…
Verastem price target lowered to $12 from $14 at Guggenheim
Guggenheim lowered the firm’s price target on Verastem (VSTM) to $12 from $14 and keeps a Buy rating on the shares after updating the firm’s model following Q2 results. Published…
Verastem Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth and expanded adoption of AVMAPKI FAKZYNJA CO-PACK, supported by robust commercial execution and $90 million in non-dilutive funding. Clinical pipeline advanced with positive data and FDA Fast Track for VS-7375, with key data updates expected in October.
Verastem Earnings release: Q2 2026
Verastem released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Verastem Quarterly report: Q2 2026
Verastem has published its Q2 2026 quarterly earnings report on August 6, 2026.
Verastem Slides: Q2 2026
Verastem has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Verastem reports Q2 adjusted EPS (31c), consensus (44c)
Reports Q2 revenue $40.1M, consensus $22.88M. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI F...
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial ...
Verastem Slides: Corporate presentation
Verastem has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Verastem doses first patients in Target-D 203 Phase 2 trial
Verastem (VSTM) Oncology “announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibit...
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer.
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Verastem doses first patient in TARGET-D 202 Phase 2 trial
Verastem (VSTM) Oncology announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in pat...
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC.
Verastem price target lowered to $14 from $15 at RBC Capital
RBC Capital lowered the firm’s price target on Verastem (VSTM) to $14 from $15 and keeps an Outperform rating on the shares as part of a broader research note previewing…
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant...
Verastem Transcript: Study update
VS-7375, a selective oral KRAS G12D inhibitor, shows promising efficacy and tolerability in phase I/II trials for pancreatic, colorectal, and lung cancers, with deep responses and manageable side effects at 900 mg. Combination strategies and pivotal trials are advancing rapidly.